Increased Plasma Levels of Tissue Factor Pathway Inhibitor (TFPI) after n-3 Polyunsaturated Fatty Acids Supplementation in Patients with Chronic Atherosclerotic Disease

Summary

This double-blind, randomised, controlled study examined the effect of a daily dosage of 3 g n-3 polyunsaturated fatty acids (n-3 PUFA) on plasma lipids and some haemostatic factors in 40 patients with chronic atherosclerotic diseases. Serum lipids, factor VII, tissue factor pathway inhibitor (TFPI) and prothrombin activation fragment 1+2 (F₁₊₂) were measured at baseline and after 2, 8, and 16-week supplementation of either n-3 PUFA or com oil. Administration of n-3 PUFA promptly lowered serum triglycerides and increased LDL-cholesterol (-32% and +33%, respectively, after 2 weeks of treatment) while a significant increase (+31%) in HDL-cholesterol was documented at the end of the observation period. Treatment with n-3 PUFA induced a progressive significant increase of TFPI plasma levels (+21% after 16 weeks; p = 0.029). TFPI activity was significantly correlated with LDL-cholesterol, and multiple stepwise regression analysis showed that LDL-cholesterol was the most important predictor of TFPI activity. Plasma levels of the inhibitor showed also a very high parallelism in their trend over time (ANOVA model for homogeneity of slopes) with both HDL-cholesterol (p = 0.82) and LDL-cholesterol (p = 0.67). Patients treated with n-PUFA also showed a significant reduction of F₁₊₂ plasma levels (p = 0.016) while no significant changes were detected in plasma factor VII clotting activity. Lipid and haemostatic parameters were not modified at any study time in patients receiving corn oil as placebo. The results of this study confirm the effects of n-3 PUFA administration on plasma lipids and show that in patients with chronic atherosclerotic disease a 16-week supplementation with these compounds induces a small but statistically significant increase of TFPI plasma levels with a parallel down-regulation of the extrinsic pathway of blood coagulation which may be relevant to the antithrombotic activity of fish diet and fish oil derivatives.

• References

• 1 Nemerson Y. Tissue factor and haemostasis. Blood 1988; 71: 1-8
• 2 Osterud B, Rapaport SI. Activation of factor IX by the reaction product of tissue factor and factor VII: Additional pathway for initiating blood coagulation. Proc Natl Acad Sci USA 1977; 74: 5260-5264
• 3 Broze Jr GJ, Girard TJ, Novotny WF. The lipoprotein associated coagulation inhibitor. In: Progress in Hemostasis and Thrombosis, Vol 10 Coller BS. ed Philadelphia: WB Saunders; 1990: 243-268
• 4 Rapaport SI. The extrinsic pathway inhibitor: A regulator of tissue factor-dependent blood coagulation. Thromb Haemost 1991; 66: 6-15
• 5 Wilcox JN, Smith KM, Scwartz SM, Gordon D. Localization of tissue factor in the normal vessel and in the atherosclerotic plaque. Proc Natl Acad Sci USA 1989; 86: 2839-2843
• 6 Meade TW, Brozovic M, Chakrabarti RR, Haines AP, Jameson JD, Mel-lowes S, Miller GJ, North WRS, Stirling Y, Thompson SG. Haemostatic function and ischaemic heart disease: Principal results of the Nortwick Park Heart Study. Lancet 1986; 2: 533-537
• 7 Wilkinson WH, Meade TW. Association between dietary intake and plasma factor VII coagulant activity. A predictor of cardiovascular mortality. Atherosclerosis 1986; 60: 269-277
• 8 Skartlien AH, Lyberg-Beckmann S, Holme I, Hjermann I, Prydz H. Effect of alteration in triglyceride levels on factor Vll-phospholipid complexes in plasma. Atherosclerosis 1989; 9: 798-801
• 9 Kromhout D, Bosschieter EB, De Lezenne Coulander C. The inverse relation between fish consumption and 20 year mortality from coronary heart disease. N Engl J Med 1985; 312: 1205-1209
• 10 Eritsland J, Seljeflot I, Abdelnoor M, Amesen H. Long-term influence of omega-3 fatty acids on fibrinolysis, fibrinogen, and serum lipids. Fibrinolysis 1994; 8: 120-125
• 11 Schmidt EB, Vanning K, Ernst E, Madsen P, Dyerberg J. Dose-response studies on the effect of n-3 polyunsaturated fatty acids on lipids and haemostasis. Thromb Haemost 1990; 63: 1-5
• 12 Bauer KA, Rosenberg RD. The pathophysiology of the prethrombotic state in humans: insights gained from studies using markers of the haemostatic system activation. Blood 1987; 70: 343-350
• 13 Von Schacky C, Fisher S, Weber PC. Long-term effects of dietary marine w-3 fatty acids upon plasma and cellular lipids, platelet function, and eico-sanoid formation in humans. J Clin Invest 1985; 76: 1626-1631
• 14 Dart AM, Riemersma RA, Oliver MF. Effect of Maxepa on serum lipids in hypercholesterolaemic subjects. Atherosclerosis 1989; 80: 119-124
• 15 Friedewald WT, Levy RI, Fredrickson DS. Estimation of the low density cholesterol in plasma without the use of the ultracentrifuge. Clin Chem 1976; 18: 449-502
• 16 Berrettini M, Malaspina M, Parise P, Lucarelli G, Kisiel W, Nenci GG. A simple chromogenic substrate assay of tissue factor pathway inhibitor activity in plasma and serum. Am J Clin Path 1995; 103: 391-395
• 17 SAS Institute Inc., SAS/STAT User’s Guide, version 6, 4th edition, Volume 2. Cary, NC: SAS Institute Inc 1989
• 18 Burr ML, Fehily AM, Gilbert JF, Rogers S, Holliday RM, Sweetnam PM, Elwood PC, Deadman NM. Effects of changes in fat, fish and fibre intake on death and myocardial infarction: Diet and reinfarction trial (DART). Lancet 1989; 2: 757-761
• 19 Ascheri A, Rimm EB, Stampfer MJ, Giovannucci EL, Willet WC. Dietary intake of marine n-3 fatty acids, fish intake, and the risk of coronary disease among men. N Engl J Med 1995; 332: 977-982
• 20 Kinsella JE, Lokesh B, Stone RA. Dietary n-3 polyunsaturated fatty acids and the amelioration of cardiovascular disease: possible mechanisms. Am J Clin Nutr 1990; 52: 1-28
• 21 Leaf A. Cardiovascular effects of fish oils. Beyond the platelet. Circulation 1990; 82: 624-628
• 22 Emeis JJ, van Houwelingen AC, van den Hoogen CM, Homstra G. A moderate fish intake increases plasminogen activator inhibitor type-1 in human volunteers. Blood 1989; 74: 233-237
• 23 Harris WS. Fish oils and plasma lipid and lipoprotein metabolism in humans: a critical review. J Lipid Res 1989; 30: 785-790
• 24 Novotny WF, Girard TJ, Miletich JP, Broze GJ. Purification and characterization of the lipoprotein-associated coagulation inhibitor from human plasma. J Biol Chem 1989; 264: 18832-18837
• 25 Lesnik P, Vonica A, Guerin M, Morea M, Chapman MJ. Anticoagulant activity of tissue factor pathway inhibitor in human plasma is preferentially associated with dense subspecies of LDL and HDL and with Lp(a). Arteri-oscl Thromb 1993; 13: 1066-1075
• 26 Sandset PM, Lund H, Norseth J, Abildgaard U, Ose L. Treatment with hy-droxymethylglutaryl-coenzyme A reductase inhibitors in hypercholesterolemia induces changes in the components of the extrinsic coagulation system. Arterioscl Thromb 1991; 11: 138-145
• 27 Hansen JB, Huseby NE, Sandset PM, Svensson B, Lyngmo V, Nordpi A. Tissue-factor pathway inhibitor and lipoproteins. Evidence for association with and regulation by LDL in human plasma. Arterioscl Thromb 1994 14. 223-239
• 28 Moor E, Hamsten A, Karpe F, Bavenholm P, Blomback M, Silveira A. Relationship of tissue factor pathway inhibitor activity to plasma lipoproteins and myocardial infarction at a young age. Thromb Haemost 1994; 71: 707-712
• 29 Kokawa T, Abumiya T, Kimura T, Harada-Shiba M, Koh H, Tsushima M, Yamamoto A, Kato H. Tissue factor pathway inhibitor activity in human plasma. Measurement of lipoprotein-associated and free forms in hyper-lipidemia. Arterioscler Thromb 1995; 15: 504-510
• 30 Nilsen SWT, Dalaker K, Nordpy A, Osterud B, Ingebretsen OC, Lyhgmo V, Almdahl S, Vaage J, Rasmussen K. Influence of a concentrated ethyl-ester compound on n-3 fatty acids on lipids, platelets and coagulation in patients undergoing coronary bypass surgery. Thromb Haemost 1991; 66: 195-201
• 31 Haskel EJ, Torr SR, Day KC, Palmier MO, Wun TC, Sobel BE, Abend-schein DR. Prevention of arterial reocclusion after thrombolysis with recombinant lipoprotein-associated coagulation inhibitor. Circulation 1991; 84: 821-827
• 32 Almus FE, Rao LVM, Rapaport SI. Regulation of factor Vila/tissue factor functional activity in an umbilical vein model. Arterioscl Thromb 1993; 13: 105-111
• 33 Hansen JB, Svensson B, Wilsgard L, Osterud B. Serum enriched with n-3 polyunsaturated fatty acids inhibits procoagulant activity in endothelial cells. Blood Coagul Fibrinolysis 1991; 2: 519-523
• 34 Sandset PM, Wam-Cramer BJ, Rao LVM, Maki SL, Rapaport SI. Depletion of extrinsic pathway inhibitor (EPI) sensitizes rabbits to disseminated intravascular coagulation induced with tissue factor: evidence supporting a physiologic role for EPI as a natural anticoagulant. Proc Natl Acad Sci USA 1991; 88: 708-712